Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY | Market Cap | 8.67T +31.5% |
| Revenue (ttm) | 4.46T -2.5% |
| Net Income | 112.93B -45.7% |
| EPS | 70.47 -45.9% |
| Shares Out | 1.58B |
| PE Ratio | 77.88 |
| Forward PE | 31.76 |
| Dividend | 200.00 (3.69%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 6,752,600 |
| Average Volume | 5,757,860 |
| Open | 5,515.00 |
| Previous Close | 5,488.00 |
| Day's Range | 5,441.00 - 5,616.00 |
| 52-Week Range | 3,916.00 - 5,616.00 |
| Beta | 0.08 |
| RSI | 78.99 |
| Earnings Date | Jan 29, 2026 |
About TYO:4502
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, TYO:4502's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.
Financial StatementsNews
Q3 2026 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript
Q3 2026 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript
Takeda Tests New Highs, But Struggles To Find Entyvio Successor
Takeda Pharmaceuticals is downgraded from buy to hold after reaching 52-week highs, with valuation no longer compelling. TAK's Q3 earnings were resilient despite US revenue declining 9.1%; margin impr...
Takeda Pharmaceutical Company Limited (TAK) Q3 FY2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript
Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control
Takeda Pharmaceutical Company Limited (NYSE: TAK) posted a third-quarter 2025 adjusted net profit of 235 billion Japanese yen (approximately $1.53 billion). The company reported earnings per American...
Earnings Scheduled For January 29, 2026
Companies Reporting Before The Bell • MOGU (NYSE: MOGU) is estimated to report earnings for its first quarter. • Trane Technologies (NYSE: TT) is likely to report quarterly earnings at $2.82 per sha...
Takeda Pharmaceutical Non-GAAP EPS of ¥428.00, revenue of ¥3411.2B; updates FY26 outlook
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incrementa...
Takeda Pharmaceutical Q3 Earnings Preview
Insights into Takeda Pharmaceutical's Upcoming Earnings
Takeda Pharmaceutical (NYSE: TAK) is set to give its latest quarterly earnings report on Thursday, 2026-01-29. Here's what investors need to know before the announcement. Analysts estimate that Taked...
Takeda Announces US Availability Of GAMMAGARD LIQUID ERC For Primary Immunodeficiency Treatment
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), Thursday announced the U.S. availability of GAMMAGARD LIQUID ERC, which is approved as a replacement therapy for people two years of age and ol...
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA i...
Independence Bank of Kentucky Buys 201 Shares of Takeda Pharmaceutical Co Ltd (TAK)
Independence Bank of Kentucky Buys 201 Shares of Takeda Pharmaceutical Co Ltd (TAK)
Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Takeda Pharmaceutical, Protagonist Therapeutics Announces Submission Of NDA For Rusfertide
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) and Protagonist Therapeutics, Inc. (PTGX), Monday announced the submission of a New Drug Application regarding rusfertide for the treatment of a...
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Applica...
Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug
Takeda Pharmaceutical Co., Ltd (NYSE: TAK) on Thursday announced positive topline results for the two pivotal Phase 3 studies of zasocitinib (TAK-279) for moderate-to- severe plaque psoriasis (PsO) ....
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies.
Takeda's Phase 3 Study Of Oral Zasocitinib In Plaque Psoriasis Achieves Primary Endpoints
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) Thursday reported that its Phase 3 studies of once-daily oral Zasocitinib met all primary and ranked secondary endpoints in adults with moderate-to-sev...
Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment...
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from th...
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and...
US FDA investigates death tied to Takeda's blood disorder drug
The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder drug, the health regulator said on Friday.
Takeda blood disorder therapy Adzynma linked to patient death: FDA
Takeda Pharmaceutical (TAK) stock is in focus as the company's blood disease drug Adzynma is linked to a patient death, according to the FDA. Read more here.